KSM-66 Cortisol Reduction 2012 Landmark Study

Last updated: October 4, 2026 - Reviewed by Verdant Wellness Editorial Team

Table of Contents

• What Is the 2012 KSM-66 Cortisol Landmark Study?
• Study Design: How the Trial Was Conducted
• Key Results: Cortisol, Stress, and Anxiety Outcomes
• What Makes KSM-66 Different From Regular Ashwagandha?
• Who Does KSM-66 Actually Work For?
• What Research Came After the 2012 Study?
• Safety Profile: What the Data Shows
• Frequently Asked Questions
• Bottom Line: What the Science Actually Says

What Is the 2012 KSM-66 Cortisol Landmark Study?

In 2012, a team of researchers led by Dr. K. Chandrasekhar published what would become one of the most cited clinical trials in adaptogen science. The study, formally titled "A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root," appeared in the Indian Journal of Psychological Medicine (2012;34(3):255–262).

The Chandrasekhar ashwagandha study was the first rigorously designed randomized controlled trial to measure not just subjective feelings of stress, but actual ashwagandha serum cortisol levels in chronically stressed human adults. This distinction matters enormously. Prior to this study, much of the evidence supporting ashwagandha as a stress-reducing herb came from animal models, traditional Ayurvedic documentation, or loosely controlled human observations. Chandrasekhar's team changed that conversation entirely.

The reason this trial carries so much weight over a decade later is straightforward: it used a gold-standard methodology — a double-blind, placebo-controlled, randomized design — and it measured hard biological endpoints alongside validated psychological scales. When the results came in, they were striking enough that the KSM-66 cortisol reduction data continues to be referenced in product literature, meta-analyses, and clinical guidance to this day.

This article breaks down exactly what that study found, what it means for you, and how the science has evolved since.

★★★★★ 4.8 · 1,247 reviews

Feel Calm By Bedtime. Focused By Morning.

Adaptogen-based formula. Third-party tested. Made in an FDA-registered facility. Backed by a 60-day money-back guarantee.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

Study Design: How the Trial Was Conducted

Understanding the methodology is essential for evaluating what the KSM-66 cortisol 2012 data actually proves — and what it does not.

Participants

The ashwagandha randomized controlled trial enrolled 64 adults between the ages of 18 and 54 who reported experiencing chronic psychological stress. Participants were otherwise healthy, without serious medical conditions, and were not taking other medications that could confound cortisol readings or psychological outcomes. Individuals were recruited specifically because they reported symptoms consistent with stress — not because they had clinical diagnoses of anxiety disorders or depression.

This population choice was deliberate. The researchers wanted to study what might be called the "chronically stressed but otherwise well" adult — a profile that reflects a large portion of the real-world audience for adaptogenic supplements.

Randomization and Blinding

Participants were randomly assigned in a 1:1 ratio to either:

• KSM-66 Ashwagandha group: 300 mg capsules taken twice daily (600 mg total per day)
• Placebo group: Identical-looking capsules containing an inert substance

Both participants and researchers evaluating outcomes were blinded to group assignment, satisfying the requirements for a true double-blind design. This controls for the powerful placebo effect that frequently inflates perceived improvements in stress and anxiety studies.

Duration

The intervention ran for 60 days, a duration considered sufficient to observe meaningful cortisol modulation and psychological adaptation without the confounds that might emerge in very long-term trials (e.g., lifestyle changes, seasonal variation).

Outcome Measures

The Chandrasekhar team used a multi-layered measurement approach, which is one reason this study remains methodologically credible:

Biological endpoint:

• Serum cortisol — measured via blood draw at baseline and end of study

Validated psychological scales:

• Perceived Stress Scale (PSS) — a widely validated 10-item questionnaire measuring subjective stress
• General Health Questionnaire-28 (GHQ-28) — assessing somatic symptoms, anxiety, insomnia, social dysfunction, and severe depression
• Depression, Anxiety and Stress Scale (DASS) — measuring three related but distinct negative emotional states

The combination of an objective biomarker (cortisol) and multiple validated self-report instruments gave the study a level of rigor that single-measure trials cannot match.

Key Results: Cortisol, Stress, and Anxiety Outcomes

Here is where the KSM-66 anxiety stress study data becomes genuinely compelling. The results across every single outcome measure favored the ashwagandha group, and many of those differences were statistically highly significant.

Primary Outcome: Serum Cortisol

This is the headline finding of the cortisol reduction RCT.

| Metric | KSM-66 Group | Placebo Group | Statistical Significance | |:---|:---|:---|:---| | Serum Cortisol Reduction | 27.9% from baseline | 7.9% from baseline | P = 0.0006 |

The ashwagandha cortisol placebo comparison here is critical. The placebo group did experience a modest cortisol reduction — about 7.9% — which is itself informative. It tells us that the act of participating in a structured health study, taking a daily supplement, and receiving some level of attention has a real (if modest) cortisol-lowering effect. That's the placebo response doing its job.

But the KSM-66 group's 27.9% reduction was nearly 3.5 times larger — and this gap was highly statistically significant at P = 0.0006, meaning there is less than a 0.06% probability this difference occurred by chance alone. This is strong evidence for a genuine biological effect on cortisol regulation.

Perceived Stress Scale (PSS)

The subjective experience of stress mirrored the cortisol data, but with even more dramatic effect sizes.

| Metric | KSM-66 Group | Placebo Group | Statistical Significance | |:---|:---|:---|:---| | PSS Score Reduction | 44.0% | 5.5% | P < 0.0001 |

A 44% reduction in perceived stress versus 5.5% in the placebo group. The P < 0.0001 threshold is the highest level of statistical confidence typically reported in clinical literature. This is not a marginal finding.

GHQ-28 and DASS Subscales

The ashwagandha cortisol clinical benefits extended across nearly every domain of psychological and somatic functioning measured:

| Scale / Subscale | KSM-66 Reduction | |:---|:---| | GHQ-28 (Overall Stress) | 72.3% | | DASS (Depression/Anxiety/Stress) | 71.6% | | GHQ-28 (Somatic Symptoms) | 76.1% | | GHQ-28 (Anxiety and Insomnia) | 69.7% |

These numbers are remarkably consistent. Across somatic symptoms, anxiety, insomnia, and composite stress measures, participants taking KSM-66 showed reductions in the 69–76% range. Even accounting for the fact that psychological self-report scales can amplify perceived improvements, the simultaneous reduction in objective serum cortisol makes these findings significantly more credible.

What the Researchers Concluded

The KSM-66 study authors concluded that high-concentration, full-spectrum ashwagandha root extract "safely and effectively improves an individual's resistance towards stress and thereby improves self-assessed quality of life." Crucially, they framed this within the context of adaptogen science — the idea that certain botanicals can help normalize the physiological stress response rather than simply sedating it.

The combination of a 27.9% ashwagandha serum cortisol reduction with near-significant improvements across all psychological measures made this the most complete, well-controlled evidence of ashwagandha's stress-modulating properties published up to that point.

★★★★★ 4.8 · 1,247 reviews

The Adaptogens Your Nervous System Has Been Missing.

Ashwagandha, rhodiola, and phosphatidylserine — clinically-studied ingredients that support healthy cortisol rhythms.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

What Makes KSM-66 Different From Regular Ashwagandha?

This is a question that matters practically if you are considering supplementation, and the KSM-66 cortisol reduction results cannot be generalized to all ashwagandha products indiscriminately.

The Proprietary Extraction Process

KSM-66 is a trademarked, standardized extract developed by Ixoreal Biomed. It is produced exclusively from ashwagandha root — not leaves, stems, or whole-plant material — using a proprietary extraction process that the manufacturer describes as preserving the natural balance of constituents found in the root, without the use of alcohol solvents.

The key standardization target is withanolides, the primary bioactive compounds in ashwagandha. KSM-66 is standardized to contain a minimum of 5% withanolides by weight, which is a higher concentration than most generic ashwagandha powders or non-standardized extracts.

Why Root-Only Matters

Traditional Ayurvedic use of ashwagandha is based almost entirely on root preparations. The leaves contain a different withanolide profile — including higher concentrations of withaferin A — which has a distinct pharmacological activity and may not be appropriate for the stress-reduction applications documented in the clinical literature.

Generic ashwagandha supplements may use whole-plant material, leaves, or unstandardized root powder with variable withanolide content. This means the compound responsible for the cortisol-modulating effects documented in the Chandrasekhar study may be present in substantially different concentrations.

What This Means for Interpreting the Data

When reviewing the KSM-66 cortisol 2012 results, it is important to understand that the 27.9% cortisol reduction was achieved specifically with:

• KSM-66 extract (not generic ashwagandha)
• Root-only material standardized to ≥5% withanolides
• A dose of 600 mg per day (300 mg twice daily)
• A duration of 60 days in chronically stressed adults

Extrapolating these results to a generic ashwagandha powder at a different dose, from a different plant part, with an unknown withanolide content is scientifically unjustified. The ashwagandha cortisol clinical evidence is extract-specific, not blanket-herb-specific.

Who Does KSM-66 Actually Work For?

One of the most important nuances to communicate honestly about the KSM-66 anxiety stress study data is that these results were demonstrated in a specific population — and the effect size appears to be meaningfully tied to baseline stress levels.

Chronically Stressed Adults

The Chandrasekhar study enrolled individuals who reported experiencing chronic psychological stress. This is the population for whom the evidence is strongest. The 27.9% ashwagandha serum cortisol reduction is most applicable to adults who have elevated cortisol due to sustained psychological or occupational stress.

Normal-Range Cortisol: A More Modest Effect

An important distinction that many supplement marketing materials overlook: KSM-66 appears to show a moderate effect in stressed adults but has a minimal effect in those with already-normal cortisol levels. This makes biological sense — adaptogens are generally theorized to work by normalizing dysregulated systems rather than pushing physiological markers in a single direction regardless of baseline state.

If your cortisol is already in a healthy range, you should expect a much smaller reduction — possibly negligible — even at the 600 mg/day dose used in the cortisol reduction RCT.

Adults With Stress-Related Insomnia

Follow-up research published in 2019 by Langade et al. extended the KSM-66 study findings to sleep outcomes. That trial found that KSM-66 supplementation improved sleep onset latency, sleep quality, and morning alertness in adults reporting stress-related sleep disturbance. This is clinically relevant because elevated cortisol in the evening is one of the primary mechanisms by which chronic stress disrupts sleep architecture.

Those Seeking Metabolic Support

Later research (approximately 2022) began examining KSM-66 in the context of metabolic outcomes. One trial noted approximately a 3% reduction in body weight in the KSM-66 group compared to 1.4% in placebo — an effect hypothesized to be mediated at least in part through cortisol reduction, since chronic cortisol elevation promotes visceral fat accumulation. This is a secondary finding and should not be interpreted as a primary weight-loss effect.

Who Is NOT the Right Candidate

• Individuals with normal-to-low cortisol levels seeking further reduction
• People expecting results within days (the study used a 60-day protocol)
• Those with clinical anxiety disorders or depression as a substitute for evidence-based treatments
• Individuals taking medications that affect the HPA axis without medical supervision

What Research Came After the 2012 Study?

A common question is whether more recent research — particularly from 2024 to 2026 — has replicated or updated the ashwagandha randomized controlled findings from Chandrasekhar's team. The honest answer requires some nuance.

No Direct Replication Published Between 2024–2026

No specific research replicating the 2012 KSM-66 cortisol landmark study was published between 2024 and 2026. This is not because the findings were challenged or abandoned — it is because the scientific community generally does not fund direct replications of already well-established results when resources can be directed toward extending those findings into new domains.

The 2012 findings are now considered the established baseline for KSM-66 cortisol reduction, and subsequent research has built on them rather than repeated them.

Key Post-2012 Milestones

2019 — Sleep and Insomnia (Langade et al.) This trial extended the KSM-66 evidence base into sleep medicine, finding significant improvements in sleep quality, sleep efficiency, and subjective well-being in adults with insomnia. Cortisol's role in disrupting sleep architecture made this a logical and important next step from the 2012 findings.

What the Trajectory Tells Us

The evolution of the KSM-66 study evidence base follows a typical pattern for well-supported botanical interventions: early foundational trial establishes mechanism and effect size, subsequent trials expand into related domains, and later literature synthesizes the full body of evidence. The absence of a 2024–2026 direct replication of the cortisol trial is not a gap — it reflects scientific confidence in the original findings combined with a rational allocation of research resources toward unanswered questions.

★★★★★ 4.8 · 1,247 reviews

See Why Athletes And Executives Take It Daily.

Adaptogen-based formula, third-party tested, made in the USA. Cancel subscription anytime.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

Safety Profile: What the Data Shows

No clinical review is complete without an honest assessment of safety. The ashwagandha cortisol clinical literature has accumulated a meaningful safety dataset since 2012.

Safety in the 2012 Trial

In the original Chandrasekhar study, the KSM-66 group reported only mild adverse effects, primarily gastrointestinal in nature (mild nausea or stomach discomfort). No serious adverse events were recorded. Dropout rates were similar between active and placebo groups, suggesting the supplement was well-tolerated across the study population.

Preclinical Toxicology

A 90-day repeated dose toxicity study in rats found KSM-66 to be safe at doses up to 2,000 mg/kg/day — a level far exceeding any human therapeutic dose when body weight scaling is applied. Organ function, hematological parameters, and behavioral assessments showed no significant adverse effects at these doses.

Human Trial Safety Data Summary

Across multiple clinical trials involving KSM-66:

• Adverse effects reported: Generally mild and transient, including occasional gastrointestinal discomfort, headache, or drowsiness
• Serious adverse events: None documented in controlled trials at the 600 mg/day reference dose
• Liver safety: Rare case reports of hepatotoxicity have been associated with ashwagandha use generally (not specifically KSM-66 in controlled settings), highlighting the importance of appropriate dosing and medical consultation for individuals with hepatic concerns
• Drug interactions: Limited formal data; theoretical interactions with thyroid medications, immunosuppressants, and sedatives have been noted and warrant caution

Populations Requiring Caution

• Pregnant women: Ashwagandha is contraindicated in pregnancy due to potential uterotonic effects
• Autoimmune conditions: The immunomodulating properties of withanolides may theoretically exacerbate autoimmune activity
• Thyroid disorders: Some evidence suggests KSM-66 may modestly increase thyroid hormone levels; those on thyroid medications should consult a physician
• Pre-surgical patients: Discontinue at least two weeks before surgery due to potential interactions with anesthesia

Frequently Asked Questions

What exact dose was used in the 2012 study?

The Chandrasekhar ashwagandha study used 600 mg per day, delivered as two 300 mg capsules — one in the morning and one in the evening. This has become the reference dose for the majority of subsequent KSM-66 trials, and most clinical recommendations for stress and cortisol management cite this 600 mg/day figure as the evidence-based target.

Does KSM-66 only work if your cortisol is high?

This is one of the most clinically important questions about ashwagandha cortisol placebo-controlled research. The available evidence suggests KSM-66 shows its most robust cortisol-reducing effects in individuals with elevated cortisol due to chronic stress. For people with already-normal cortisol levels, the effect appears minimal. This is consistent with adaptogenic theory — these compounds modulate dysregulated systems rather than unilaterally suppressing cortisol regardless of baseline.

Is KSM-66 the same as any ashwagandha supplement?

No. The KSM-66 cortisol reduction results are specific to this proprietary extract, which is root-only, standardized to a minimum 5% withanolides, and produced through a specific extraction process. Generic ashwagandha supplements with unstandardized withanolide content, whole-plant sourcing, or different extraction methods cannot be expected to produce the same outcomes documented in the KSM-66 cortisol 2012 literature.

How long does it take to see results?

The cortisol reduction RCT demonstrated significant results over a 60-day intervention. There is no published evidence of significant cortisol reduction in shorter timeframes with ashwagandha. Individuals should not expect meaningful cortisol changes within the first one to two weeks of supplementation.

Has the 2012 study been independently replicated?

The specific ashwagandha randomized controlled methodology from Chandrasekhar's 2012 study has not been directly replicated in an independent trial. However, subsequent trials and meta-analyses have consistently supported the stress- and cortisol-reducing effects of KSM-66 across different populations and study designs. The overall direction of evidence is strongly consistent with the original findings.

Does KSM-66 help with sleep?

Yes, though this is based on the 2019 Langade trial rather than the 2012 study. That research specifically examined KSM-66 in adults with insomnia and found improvements in sleep onset latency, sleep quality, and morning alertness. Given the mechanistic link between elevated evening cortisol and poor sleep quality, this outcome is consistent with the cortisol-modulating mechanism established in the KSM-66 anxiety stress study.

Can I take KSM-66 with other supplements?

Most clinical trials have studied KSM-66 as a standalone intervention. Common co-administration with magnesium, L-theanine, or B-vitamins occurs in commercial formulations, but formal interaction data is limited. For medically complex individuals — particularly those on prescription medications — consultation with a healthcare provider before adding KSM-66 is appropriate.

Bottom Line: What the Science Actually Says

The KSM-66 cortisol reduction 2012 landmark study by Chandrasekhar and colleagues remains, more than a decade after its publication, one of the best-designed and most reproducibly cited trials in the adaptogen literature. Its methodology — a rigorously blinded ashwagandha randomized controlled trial measuring both objective serum cortisol and multiple validated psychological scales — set a standard that most botanical supplement research still struggles to meet.

The core findings deserve to be stated plainly:

• KSM-66 at 600 mg/day reduced serum cortisol by 27.9% compared to 7.9% in the placebo group (P = 0.0006) over 60 days
• Perceived stress dropped by 44% versus 5.5% in placebo (P < 0.0001)
• Anxiety, depression, and somatic stress markers all showed reductions in the 69–76% range across GHQ-28 and DASS subscales
• These findings apply specifically to chronically stressed adults using the KSM-66 proprietary extract — not to all ashwagandha products or all populations

The fact that no direct replication was published between 2024 and 2026 does not weaken these conclusions. It reflects a scientific literature that has moved forward from this established baseline — extending into sleep medicine, metabolic health, testosterone, and broader quality-of-life applications — rather than repeatedly proving something already well-established.

What the evidence does not support is equally worth stating: KSM-66 is not a substitute for evidence-based treatment of clinical anxiety or depression, it is not a cortisol suppressant that works regardless of baseline stress levels, and the ashwagandha cortisol clinical benefits documented in this trial cannot be assumed from generic, unstandardized ashwagandha products.

For individuals who are chronically stressed, not managing a diagnosed clinical disorder, and willing to commit to a 60-day trial at the evidence-based 600 mg/day dose, the KSM-66 study data represents some of the most robust clinical support available for any adaptogenic botanical supplement currently on the market.

★★★★★ 4.8 · 1,247 reviews

Ready To Try Adaptogen-Based Cortisol Support?

Third-party tested. 60-day guarantee. Free shipping over $40. Ships in 24 hours.

Shop Cortisol Drops →

✓ 60-day guarantee ✓ Free shipping $40+ ✓ Ships in 24hrs

This article is intended for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning any supplement regimen, particularly if you have existing health conditions or take prescription medications.

Sources:

1. Chandrasekhar K, et al. "A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root." Indian Journal of Psychological Medicine. 2012;34(3):255–262.
2. Nutritional Outlook. "KSM-66 Brand Ashwagandha Reduces Stress, Study Confirms." nutritionaloutlook.com.
3. NutraIngredients. "The most clinically proven ashwagandha for stress." nutraingredients.com.
4. Langade D, et al. "Efficacy and safety of Ashwagandha root extract in insomnia and anxiety." Cureus. 2019.
5. Unived. "Ashwagandha and cortisol reduction: what the evidence actually shows." unived.com.